NCT05196347View on ClinicalTrials.gov

Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions

Chronic Kidney Diseases

Interventions

DRUG

Dapagliflozin

In dapagliflozin arm, subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip \<20%.

Trial Locations (1)

Unknown

Chi-Chih Hung, Kaohsiung City

All Listed Sponsors

lead

Kaohsiung Medical University

OTHER